The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01155180
Recruitment Status :
First Posted : July 1, 2010
Results First Posted : April 7, 2017
Last Update Posted : April 7, 2017
Beth Israel Deaconess Medical Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by (Responsible Party):
Christos Mantzoros, Beth Israel Deaconess Medical Center
Subjects who have successfully completed 1of the 4 hospital-based participating weight loss programs (Boston Medical Center, Tufts Medical Center, Massachusetts General Hospital, Beth Israel Deaconess Medical Center (BIDMC)-Joslin Center) & have achieved a >8% (average 10%, range 8-14%) weight loss will be invited to participate in the study.
We will start the leptin at a dose ...
We will start the placebo at a dose...
We will start the leptin at a dose of 0.08mg/kg fat mass in men and 0.14mg/kg fat mass in women
Leptin: Hormone - daily self injections for 6 months
We will start the placebo at a dose of 0.08mg/kg fat mass in men and 0.14mg/kg fat mass in women